Dennis M. Mcgrath - 07 Nov 2024 Form 4 Insider Report for Citius Pharmaceuticals, Inc. (CTXR)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
12 Nov 2024, 17:00:20 UTC
Prior SEC filing
14 Aug 2024
Next SEC filing
16 Dec 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Alexander M. Donaldson, by power of attorney

Key filing fact

Dennis M. Mcgrath filed Form 4 for Citius Pharmaceuticals, Inc. (CTXR) on 12 Nov 2024.

Key facts

  • This page summarizes Dennis M. Mcgrath's Form 4 filing for Citius Pharmaceuticals, Inc. (CTXR).
  • 1 reported transaction and 3 derivative rows are listed below.
  • Accepted by SEC: 12 Nov 2024, 17:00.

Change

  • Previous filing in this sequence was filed on 14 Aug 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CTXR transaction Derivative

Stock Option (Right to Purchase Common Stock)

Award

Transaction value
$0
Shares
+125,000
Change %
Price
$0.000000
Shares after
125,000
Date
07 Nov 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
125,000
Exercise price
$0.3800
Footnotes
F1
CTXR holding Derivative

Stock Option (Right to Purchase Common Stock)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
75,000
Date
07 Nov 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
75,000
Exercise price
$0.7000
Footnotes
F2
CTXR holding Derivative

Stock Option (Right to Purchase Common Stock)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
75,000
Date
07 Nov 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
75,000
Exercise price
$1.42
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The options were granted on November 7, 2024. The options will vest 100% on the one-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of the vesting date.

Footnote F2

The options are vested in full and exercisable immediately.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .